NCT01715350View on ClinicalTrials.gov

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

151

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

September 30, 2014

Study Completion Date

June 30, 2015

Conditions
Alzheimer's Disease
Interventions
DRUG

PM012

"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"

DRUG

Placebo

"* The drug will be taken with water within 30 minutes after breakfast and supper.~* 650mg/1 tablet, PO, 12weeks"

Trial Locations (4)

130-872

Kyung Hee University Oriental Medicine Hospital, Seoul

410-719

National Health Insurance Corporation Ilsan Hospital, Goyang

442-72

The Catholic University of Korea, St. Vincent's Hospital, Suwon

137-701

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul

All Listed Sponsors
collaborator

ADM Korea Inc

INDUSTRY

lead

VTBIO Co. LTD

INDUSTRY

NCT01715350 - Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease | Biotech Hunter | Biotech Hunter